Biogen to spin off hemophilia drugs and focus on core neuro business

(Reuters) - Biogen Inc plans to spin off its hemophilia drug business as a publicly traded company, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases, the company said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news